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1. INTRODUCTION 
 
1.1 Epidemiology 
Soft tissue sarcomas (STS) are a rare and heterogeneous group of mesenchymal 
tumors, representing only 1% of all adult malignancies [1, 2]. The incidence in Europe 
is increasing and has been recently reported as 4 per 100,000 people per year [3]. 
These tumors are highly heterogeneous in their histopathology and tendency for 
aggressive behavior and they can occur in all age groups and in a variety of 
anatomic sites [4]. The lower extremity appears to be the most commonly affected 
site, with approximately 28% of all STS arising there [5]. Mortality rates of up to 50% 
for patients with STS have been previously reported [6]. The overall survival of 
patients with STS has recently been reported as 75% at 5 years following treatment 
[7]. 
 
1.2 Diagnosis 
The diagnosis of STS can be clinically challenging as these tumors are commonly 
painless, difficult to palpate and are often located deeply in proximal parts of the body 
[8]. In addition, STS do not commonly cause symptoms such as fever or night sweats 
and are not associated with weight loss or cachexia [9]. Any soft tissue mass should 
be assessed with the awareness that it may represent a sarcoma [9]. Features of a 
soft tissue mass that are suggestive of malignancy include pain or tenderness, a 
rapid increase in size, lesions larger than 5 cm in diameter and a location that is 
intramuscular or extending towards the deep fascia [9].  
Further imaging of a suspicious lesion is often helpful in establishing the diagnosis 
[10]. The size of the lesion and its relationship to the fascia can initially be assessed 
by an ultrasound examination [9]. However, magnetic resonance imaging (MRI) is 
considered the standard imaging modality for diagnosing soft tissue lesions and 
provides useful information and anatomical detail necessary for the surgical planning 
process [9]. Gadolinium enhancement helps demonstrate the vascularity of the lesion 
and its anatomical relation to blood vessels and nerves [10]. Computed tomography 
(CT) imaging can be used as an alternative when an MRI examination is not feasible. 
A chest CT scan should be carried out as part of the screening process for metastatic 
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disease [8]. Positron emission tomography (PET) scanning is developing an 
increasing role in the investigation of STS as it provides information on the biological 
activity of tissue, particularly when screening for metastatic disease and involvement 
of lymph nodes, as well as assessing the response to neoadjuvant therapy [8, 9].  A 
correlation between tumor grade and FDG uptake has been shown, allowing the 
potential future use of FDG PET scans as both a diagnostic and prognostic tool in 
patients with STS [11, 12]. Furthermore, different radiotracers in addition to FDG, 
such as AIB and O15-water, have been used to identify viable tumor tissue [13, 14].   
Obtaining a biopsy is essential in identifying the histopathological subtype of the 
tumor. Although needle biopsies are associated with fewer complications, open or 
trucut biopsies are often preferred due to their superior diagnostic accuracy regarding 
the histologic cell type and grade [8]. This procedure should be carried out after MRI 
imaging has taken place, as the biopsy may cause local trauma to the surrounding 
tissues and compromise the interpretation of the MRI images [9]. Furthermore, the 
biopsy incision should be made in line with future incisions for resections [9]. The 
exposure of neurovascular structures should be avoided in the extremities [15, 16].  If 
the placement of drains is necessary, they should be brought out in an imaginary line 
extending from the incision [15]. The biopsy should ideally be performed by the 
surgeon who will be carrying out the definitive resection of the tumor to ensure its 
correct placement [7]. 
 
1.3 Staging 
The preoperative planning of the tumor resection, particularly regarding the surgical 
margins, relies heavily on local staging of the tumor [7]. MRI is the imaging modality 
of choice for local staging [9]. Systemic staging involves screening for metastatic 
disease. Radiographic or CT imaging of the lungs is essential as STS metastasize 
predominantly to the lungs [9]. The main staging systems in current use are the 
American Joint Committee on Cancer/International Union Against Cancer 
(AJCC/UICC) system [17] and the Musculoskeletal Tumor Society (MSTS) staging 
system [18]. Both systems require the tumor grade (G1/G2/G3 for the AJCC/UICC 
system and high vs. low grade, G1/G2, for the MSTS system) and the absence or 
presence of metastases, M0 or M1 respectively. The location of the tumor, confined 
to an anatomic compartment (T1) or extracompartmental (T2), is incorporated into 
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the MSTS system. The AJCC/UICC system also includes the tumor size (T1: 
maximum diameter < 5 cm, T2: maximum diameter > 5 cm) and the absence or 
presence of regional lymph node involvement, N0 and N1 respectively. Both staging 
systems are summarized in tables 1 and 2. 
Table 1. AJCC/UICC staging system for STS [17] 
Stage 4 Tumor Components 
IA 
IB 
IIA 
IIB 
IIIA 
IIIB 
IVA 
IVB 
G1, T1, N0, M0 
G1, T2, N0, M0 
G2, T1, N0, M0 
G2, T2, N0, M0 
G3, T1, N0, M0 
G3, T2, N0, M0 
any G, any T, N1, M0 
any G, any T, any N, 
M1 
 
Table 2. MSTS staging system for STS [18] 
Stage 3 Tumor 
Components 
IA 
IB 
IIA 
IIB 
III 
G1, T1, M0 
G1, T2, M0 
G2, T1, M0 
G2, T2, M0 
any G, any T, M1 
 
1.4 Histopathology  
Accurate diagnosis and identification of the histopathologic subtype of STS is 
essential in planning the correct treatment regime, particularly when deciding whether 
neoadjuvant or adjuvant radiation therapy or which chemotherapy agents are 
appropriate [7]. At least 50 histologic subtypes have been identified, with 
undifferentiated pleomorphic sarcoma (UPS) and liposarcoma being the most 
common subtypes in adult patients [19]. The most common subtypes of STS are 
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summarized in table 3 [20]. Most STS metastasize hematogenously; some subtypes, 
such as synovial sarcoma, are however also capable of spreading through the 
lymphatic system [19]. A reference pathological examination to confirm the tumor 
histopathology is recommended due to the high rate of pathological misdiagnoses, 
reported as high as up to 30%, particularly in community pathology [21]. Stable 
chromosomal translocations found exclusively in tumor cells have been 
demonstrated in a subset of STS. These translocations provide a unique marker for 
tumor detection, such as the FUS/CHOP fusion gene in myxoid and round cell 
liposarcomas, which appear to have strong oncogenic properties [22].  
Table 3. Most common soft tissue tumors based on WHO Classification [20] 
Tissue of 
origin 
Tumor Type Subtypes 
Adipocytic Liposarcoma 6: dedifferentiated, myxoid, round cell, 
pleomorphic, mixed-type, not otherwise 
specified 
Fibroblastic/ 
Myofibroblastic 
Fibrosarcoma 4: adult fibrosarcoma, myxofibrosarcoma, 
low grade fibromyxoid (spindle cell 
tumor), sclerosing epithelioid 
So-called 
fibrohistiocytic 
Undifferentiatiated 
pleomorphic ‘MFH’ 
sarcoma (UPS) 
3: UPS, UPS with giant cells, UPS with 
prominent inflammation 
Skeletal 
muscle 
Rhabdomyosarcoma 3: embryonal, alveolar, pleomorphic 
Smooth 
muscle 
Leiomyosarcoma 
(excluding skin) 
None 
Vascular Epithelioid 
hemangioendothelioma, 
Angiosarcoma 
None 
Uncertain Synovial sarcoma, 
Epithelioid sarcoma, 
Alveolar soft part,  
Clear cell sarcoma, 
Extraskeletal Ewing 
None 
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tumor 
 
1.5  Prognosis 
There are many factors which have been shown to play an important role in 
determining the prognosis of STS. Tumor grade, in particular, has been shown to be 
an important prognostic factor in several studies [4, 23, 24]. However, Pisters et al. 
have suggested that the prognostic significance of tumor grade for distant metastasis 
decreases with time [24]. Most studies differentiated between prognostic factors for 
local disease recurrence and those for distant metastasis. 
The independent risk factors for the development of a local recurrence in a study with 
a large cohort of 1,041 patients carried out by Pisters et al. in 1996 were reported as 
presentation with local recurrent disease, positive surgical margins, patients older 
than 50 years of age and the histologic subtypes of fibrosarcoma and malignant 
peripheral nerve sheath tumor [24]. The significant prognostic factors for the 
development of distant metastases in this study were presentation with local 
recurrent disease, large tumors [> 5 cm], deep tumor location, high grade tumors and 
the histologic subtype of leiomyosarcoma [24]. The authors of this study also 
emphasized the role of histologic subtype as an independent prognostic factor, which 
was previously considered to be of secondary importance [25]. Liposarcoma was 
found to be of favorable prognostic significance in the development of metastatic 
disease [24] and has also been associated with a reduced risk of local recurrence in 
previous studies [23, 26].  
Negative surgical margins have been identified as a significant predictor of local 
disease control in many studies [23, 24, 26, 27] and are widely accepted in clinical 
practice as essential in reducing the risk of local recurrence. The surgical margins 
were, however, not found to be predictive of local disease control in a review of 211 
patients with high grade STS of the extremities carried out by Potter et al. [28]. 
Oncological reresection in patients with STS of the extremities and positive margins 
has been associated with favorable clinical outcomes [29]. Tumor localization and the 
involvement of important neighboring structures, amongst other factors, appear to 
play a key role in achieving negative margins. The rate of microscopically positive 
margins is, for example, higher in retroperitoneal STS with a rate of approximately 
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30% in primary tumors and up to 70% in resections of recurrent tumors, when 
compared to STS of the extremities [30]. On the other hand, certain cases of STS 
with vascular or neural involvement require well-planned vascular resections and 
replacement strategies to achieve negative microscopic margins [31, 32]. 
An additional prognostic factor reported by Elias et al. was the primary tumor site [4]. 
Intraperitoneal and retroperitoneal sarcomas are associated with a poorer prognosis, 
possibly due to the increased difficulty in obtaining microscopically negative margins 
in these anatomical locations, which are often in close proximity to many vital 
structures [4]. Radiation-induced sarcomas have also been associated with a poor 
prognosis despite radical resections [33]. 
The development of a local recurrence has been associated with a poor prognosis 
regarding local and distant disease control in addition to overall survival [34, 35]. 
Metastatic STS is associated with a poor overall survival, with 5-year survival rates of 
10% or less being reported in patients with pulmonary metastases not treated with a 
metastasectomy [19]. Factors which improve the prognosis of these patients include 
a single pulmonary metastatic lesion, negative resection margins after 
metastasectomy and a disease-free interval of at least 12 months prior to the 
development of metastatic disease [36]. In addition, the standardized uptake value 
(SUV) measured in FDG PET studies has demonstrated a prognostic relevance 
regarding the further course of the disease in patients with STS [12]. 
 
1.6 Treatment of STS with sciatic nerve involvement 
The treatment of STS of the lower limb with sciatic nerve involvement presents a 
unique surgical and oncological challenge. In the past, sciatic nerve involvement was 
an indication for limb amputation [37, 38]. The increased use of multimodality 
treatment, particularly adjuvant radiation therapy, has however led to less radical 
surgery with better functional outcomes [39]. More aggressive local treatment is 
usually indicated with unplanned or intralesional positive margins, such as high dose 
radiation therapy followed by a wide excision or amputation. Patient outcomes are 
still inferior despite aggressive treatment, highlighting importance of appropriate 
diagnosis and management in the initial treatment [9]. A multidisciplinary approach in 
a specialist center has been shown to significantly improve patient outcome [40]. 
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Inferior outcomes have been demonstrated in patients receiving surgical 
interventions, including biopsies, prior to referral to a multidisciplinary center [15, 16, 
41, 42]. 
 
 
1.6.1 Surgical treatment 
Surgery remains the most important factor in achieving a local disease-free state and 
maximizing function [43]. There has been a continuous shift towards preservation of 
the limb and multimodality treatment since the results of the National Cancer 
Institute’s (NCI) randomized prospective study were published in 1982 [23]. This 
study found no significant difference in the survival rates of patients with STS of the 
extremities when comparing amputation with limb sparing surgery in combination with 
radiation therapy [27]. The first report of sciatic nerve resection in a STS of the lower 
extremity in 1984 [44] was based on the hypothesis that the use of ankle-foot 
orthoses leads to a superior function of the leg when compared to hip disarticulation. 
Limb preserving surgery is currently considered the standard surgical treatment for 
STS of the lower extremity [31]. 
Local disease control is essential in the management of STS, with surgical resection 
being the only treatment modality capable of achieving a local disease-free state [43]. 
Surgical resection of STS with negative microscopic margins has been shown to 
significantly reduce the risk of local recurrence [45]. The ability to obtain wide 
margins may however be particularly challenging if the tumor is adjacent to important 
neurovascular structures. The tumor size greatly influences the ability to obtain 
negative microscopic margins, with larger tumors leading to smaller resection 
margins [43]. A resection margin of 1 to 2 mm, for example, is generally accepted 
when trying to preserve functional tissue, such as when dissecting a major nerve 
[43]. 
Regarding the tumor resection, it is more important to achieve wider margins with the 
longitudinal tumor excision compared to the transverse excision due to the growth 
pattern of STS [43]. Drains should be placed in line with the skin incision and exit 
distally in case a future secondary amputation is necessary [19]. In addition, any 
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previous incisions or tracts from biopsies or drain placements must also be excised in 
the definitive tumor resection [43]. 
For STS with vascular involvement, reasonable oncological outcomes have been 
reported with vessel reconstruction in limb salvage surgery [31, 46, 47]. Nerve 
reconstruction, on the other hand, does not guarantee preservation of function [48]. 
Tumor infiltration of the sciatic nerve has previously been an indication for limb 
amputation [37], but more recent studies have shown limb sparing surgery with 
partial or complete sciatic nerve resection to be an excellent alternative [49-52].  
The most commonly reported complications following limb sparing surgery are 
related to delayed wound healing and infection. A wound morbidity rate of 34.4% has 
been reported in en bloc resections alone without adjuvant treatment modalities [53]. 
Risk factors for developing wound complications include prolonged duration of 
surgery and adjuvant therapy, particularly neoadjuvant radiation or chemotherapy [7]. 
Postoperative delayed wound healing may also lead to a delay in commencing 
adjuvant radiation or chemotherapy. Other complications specific to limb sparing 
surgery include unplanned neurovascular injury, particularly in confined anatomical 
spaces such as the popliteal fossa, devascularization of soft tissue flaps, joint 
dislocations and fractures [7]. 
Proposed contraindications for limb sparing surgery include an expected survival of 
less than 3 months which would not justify complex surgery, significant tumor 
contamination of adjacent tissues through poorly performed biopsies or excisions or a 
pathological fracture, as well as severe local infection or systemic sepsis [7]. 
 
1.6.2 Radiation therapy 
When used as a single treatment modality, local surgical resection and marginal 
excisions of high-grade STS have been associated with high local failure rates of 70-
90% [54]. In addition, a 25% recurrence rate has been reported in patients 
undergoing radical limb sparing surgery as a single treatment modality [54]. Surgical 
resection alone has however been demonstrated to be sufficient in low grade 
subcutaneous STS of the extremities [55]. Baldini et al. also reported good local 
control rates in a cohort of 74 patients with STS of the trunk or extremities with low or 
intermediate grade small tumors when managed with surgical resection alone [56]. 
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The standard goal of surgery has always been to achieve wide margins upon tumor 
resection. The development of neoadjuvant and adjuvant radiation therapy has led to 
equivalent local control rates with focally positive marginal resections [57]. The 
beneficial effects of adjuvant radiation therapy in treating STS are generally well 
documented in the literature, with reported local control rates of 90% or greater [19]. 
Several studies found no significant difference when comparing the effects of 
neoadjuvant and postoperative radiation therapy on local and distant disease control 
or disease-free survival [58, 59]. Many authors, however, recommend neoadjuvant 
radiation therapy as it has been associated with better long term functional outcomes, 
especially in lower limbs, despite higher rates of wound complications [9, 19, 58]. 
Flugstad et al. reported major wound complications in 18% of patients treated with 
adjuvant radiation therapy compared to an incidence of up to 37% in patients treated 
with neoadjuvant radiation therapy as reported by Bujko et al. [43, 60]. An increased 
incidence of skin fibrosis, edema, joint stiffness and fracture has been shown in 
adjuvant radiation therapy [58]. Some authors argue, however, that radiation therapy 
is most effective when delivered to a low tumor load and therefore recommend 
adjuvant radiation therapy, particularly in bulky tumors [4]. The dose of radiation has 
not been found to significantly influence local disease control [23]. 
Brachytherapy refers to the implantation of a sealed radiation source, usually 
administered through the insertion of a catheter over a 3-day period, and has been 
shown to decrease local recurrence rates in some studies [61, 62]. 
 
1.6.3 Chemotherapy 
The use of adjuvant chemotherapy in non-metastatic disease is still controversial and 
is usually an individual and interdisciplinary decision, even in patients at an increased 
risk of developing metastatic disease [63]. Commonly accepted factors which favor 
the administration of adjuvant chemotherapy include local or distant disease 
recurrence, or a histologically confirmed synovial sarcoma or pediatric 
rhabdomyosarcoma [19]. High grade deeply located tumors larger than 5 cm in size 
or intermediate grade deeply located tumors larger than 10 cm in size, especially in 
younger patients, are considered a relative indication for chemotherapy [64]. 
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The standard first-line chemotherapeutic agent used for metastatic STS is 
doxorubicin. Tap et al. compared a combination of doxorubicin and olaratumab with 
doxorubicin alone an demonstrated a significant improvement of 11.8 months in the 
median overall survival was in the group of patients receiving both doxorubicin and 
olaratumab [65]. These results could lead to the addition of olaratumab in the first-line 
chemotherapeutic treatment of metastatic STS. Gronchi et al. investigated the effects 
of histology-tailored neoadjuvant chemotherapy versus the standard chemotherapy 
regime of doxorubicin and ifosfamide in a randomized phase 3 multicenter trial 
consisting of 287 patients with STS [66]. Interestingly, the group of patients receiving 
the standard chemotherapy regime demonstrated superior outcomes, particularly 
regarding the projected disease-free survival, when compared to the group receiving 
histology-tailored chemotherapy [66].  
Several studies have demonstrated the beneficial short-term effects of chemotherapy 
which were, however, not maintained over time [67-69]. When histologic subtypes of 
STS were studied separately, synovial sarcoma and pediatric rhabdomyosarcoma 
were found to have the most favorable response to chemotherapy [70]. This is 
possibly due to the potential of developing specific treatment which targets gene 
products, as these histologic subtypes of STS have known chromosomal 
translocations [70]. 
 
1.7  Postoperative follow up 
Early detection of recurrent local or metastatic disease is important and can lead to a 
prolongation of the long-term survival of these patients [43]. The surveillance of 
patients following the definitive treatment of the STS consists of monitoring the 
primary tumor site for signs of a local recurrence. This is principally carried out 
through the conduction of regular follow up appointments and physical examinations 
of the primary tumor site in addition to serial MRI scans of the site with and without 
gadolinium enhancement [19].  
Regular follow-up appointments and physical examinations of the surgical site are 
essential particularly in the early postoperative period to screen for postoperative 
complications such as wound dehiscence or devascularization of soft tissue flaps. 
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CT scans of the chest are also warranted as part of the surveillance process for 
metastatic disease as the most common site of metastases is the lung. CT scans are 
usually performed every 3 months for the first 2 years postoperatively, every 4 
months for the third year and every 6 months for the fourth and five years in patients 
with high-grade STS [19]. Such frequent CT scans of the chest are not necessary in 
patients with low-grade STS and should be selectively carried out in patients 
considered to be at high risk of developing metastatic disease, as the surveillance of 
patients at low risk of metastatic disease with regular radiographs of the chest is 
otherwise sufficient [71]. 
 
 
1.8 Aim  
Only a few reports on the outcomes of limb preserving surgery in patients with STS 
with nerve involvement have been published to date [49-52], with most studies limited 
to a small number of patients (≤20) [49-51]. The size and results of these studies 
have been summarized in table 4. In addition, no treatment guidelines exist on how 
to manage STS with major neural involvement. The aim of this study is to analyze the 
oncological and functional outcomes of limb sparing surgery in STS with sciatic nerve 
involvement. In addition, we aim to classify the degree of nerve involvement and 
suggest a treatment algorithm. 
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Table 4 Summary of studies examining patients with STS with sciatic nerve 
involvement to date [49-52] 
 
Author 
Year of 
publication 
Number 
of 
patients 
 
Summary of findings 
Bickels et 
al. 
2002 15 The sciatic nerve was resected in all patients. 
Overall function good in 11, moderate in 3 and 
poor in 1 patient. Conclusion: sciatic nerve 
resection is not an indication for amputation. 
Brooks et 
al. 
2002 18 One secondary amputation was carried out 
due to disease recurrence. The functional 
deficits were acceptable in surviving patients 
both objectively and subjectively. Conclusion: 
limb sparing surgery with sciatic nerve 
resection is an excellent alternative to limb 
amputation. 
Fuchs et 
al. 
2001 20 Patients rated their level of impairment after 
sciatic nerve resection as mild to moderate. 
Conclusion: the acceptable functional 
outcomes in patients with STS with sciatic 
nerve involvement highlights that these 
patients can be treated with limb sparing 
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surgery is an alternative to hip disarticulation or 
hindquarter amputation. 
Clarkson 
et al. 
2005 50 43 patients treated with epineural dissection 
were compared to 7 patients who were treated 
with complete resection of the sciatic nerve. 
Epineural dissection was not attempted in 
patients with tumor encasement of the nerve. 
Functional benefit of preserving the nerve by 
epineural dissection was demonstrated. 
Conclusion: resection of the sciatic nerve 
should be reserved for patients with complete 
macroscopic tumor encasement of the nerve.  
 
2. MATERIALS AND METHODS 
 
2.1 Study design and patient selection 
The data of all adult patients with STS of the extremities, truncal STS and 
retroperitoneal STS undergoing surgical treatment at the Clinical Center Frankfurt 
Höchst from January 1st 2010 until January 31st 2017 was collected in a 
computerized database on an ongoing basis and retrospectively analyzed.  Patients 
with STS of the lower limb with sciatic nerve involvement who underwent limb-
sparing surgery were selected from the database and included in this study. All 
patients were consented on the use of their clinical data for research purposes. The 
study was approved by the ethics committee of the Medical Council of the State of 
Hesse, Germany. 
Involvement of the sciatic nerve was confirmed preoperatively when CT or MRI scans 
showed no layer of normal tissue between the tumor and the sciatic nerve. For the 
purpose of this analysis, sarcomas affecting other anatomic sites or other nerves 
were excluded. 
 
 2.2 Classification of nerve involvement 
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The extent of neural involvement was assessed using high-resolution CT and MRI 
scans. Intraoperative reassessment of sciatic nerve involvement was also carried out 
by visually analyzing and palpating the relationship of the nerve to the tumor when 
possible. Intraoperative ultrasound visualizing the extent of the contact between the 
tumor and the nerve was additionally carried out in selected cases. 
STS with encasement of the nerve were classified as type A tumors. Encasement 
was defined as ≥ 180° of nerve contact with the tumor. These tumors were 
reassessed intraoperatively and were treated with en-bloc compartmental resection 
together with the nerve if the classification was confirmed. STS with direct nerve 
contact (< 180°) without encasement or disruption of its continuity were classified as 
type B and underwent compartmental resection of the tumor with epineural nerve 
dissection. STS without nerve involvement were classified as type C and were 
resected without nerve dissection or resection. The proposed classification of STS 
with sciatic nerve involvement and the suggested treatment approach has been 
summarized in Figure 1. Figures 2, 3, 4, 5, 6 and 7 are examples of MRI scans from 
six of our patients to illustrate radiological type A and type B sciatic nerve 
involvement. 
 
Figure 1. Classification of sciatic nerve involvement and suggested surgical 
treatment algorithm for patients with STS of the lower extremity 
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Figure 2. Preoperative MRI scan (T2-weighted, 1.5 Tesla) of a patient with a G3 
pleomorphic sarcoma and type A sciatic nerve involvement (source: 
Radiological Institute, Clinical Center Frankfurt Höchst) 
Limb-preserving soft tissue sarcoma resection 
 
Nerve involvement No nerve involvement 
 
Type A 
Nerve encasement  
> 180° (n = 8) 
Type B 
Nerve contact 
< 180° (n = 19) 
Type C 
(excluded from analysis) 
 
Complete nerve 
resection (n=8) 
Epineural nerve 
dissection (n=19) 
No nerve dissection 
or resection 
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Figure 3. Preoperative (left) and postoperative (right) MRI scans of a patient 
with G3 myxoid liposarcoma and type A sciatic nerve involvement (source: 
Radiological Institute, Clinical Center Frankfurt Höchst) 
  
- 20 - 
 
Figure 4. Preoperative MRI scan (T2 weighted, 1.5 Tesla) of a patient with a G2 
pleomorphic sarcoma and type A sciatic nerve involvement (source: 
Radiological Institute, Clinical Center Frankfurt Höchst) 
 
Figure 5. Preoperative MRI scan (T2 weighted fat saturated sequence, 1.5 
Tesla) of a patient with a G2 myxoid liposarcoma and type B sciatic nerve 
involvement (source: Radiological Institute, Clinical Center Frankfurt Höchst) 
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Figure 6. Preoperative MRI scan (T2 weighted fat saturated sequence, 1.5 
Tesla) of a patient with a G2 pleomorphic sarcoma and type B sciatic nerve 
involvement (source: Radiological Institute, Clinical Center Frankfurt Höchst) 
 
Figure 7. Preoperative MRI scan (T1 weighted, 3 Tesla) of a patient with a G1 
liposarcoma and type B sciatic nerve involvement (source: Radiological 
Institute, Clinical Center Frankfurt Höchst) 
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2.3 General and perioperative variables 
The presentation status of each patient (primary tumor, local recurrence or presence 
of metastatic disease) in addition to basic patient demographic data such as age, 
gender and side of the affected limb were documented. All therapeutic measures 
such as neoadjuvant or adjuvant external radiation therapy, neoadjuvant or adjuvant 
chemotherapy, isolated limb perfusion or surgical resection were carried out upon 
recommendation by a multidisciplinary tumor board and were also recorded in our 
database. En-bloc compartmental resections were carried out in accordance with the 
surgical standards described by Enneking et al. [18, 72]. Involved thigh 
compartments as well as any concurrent vascular reconstruction, plastic 
reconstruction or bone stripping were documented. An example of an en-bloc 
resection of the medial thigh compartment with partial resections of the posterior and 
anterior thigh compartment in a patient with a liposarcoma of the lower extremity with 
type B sciatic nerve involvement is displayed in figures 8 and 9. 
 
Figure 8. Intraoperative photo documentation of liposarcoma of right lower 
extremity with type B sciatic nerve involvement prior to en-bloc resection 
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Figure 9. Postoperative photo documentation following en-bloc resection of 
liposarcoma of right lower extremity with type B sciatic nerve involvement 
 
 
Assessment of tumor specimens was carried out by the in-house pathologists and 
confirmed by the reference pathological department of Heidelberg University 
Hospital. The resected tissue was assessed for histological entity, tumor size 
(maximum diameter), grade and microscopic margins. All samples were explicitly 
examined for the occurrence of histopathologic infiltration of sciatic nerve tissue by 
tumor cells. Tumor grading was based on the criteria of the “Fédération Nationale 
des Centres de Lutte Contre le Cancer” (FNCLCC), which takes cell differentiation, 
mitotic activity and necrosis into consideration [73]. The FNCLCC grading system is 
summarized in table 5. The duration of surgery, incidence of surgical and medical 
complications, reoperations and the duration of hospital stay were also recorded. 
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Table 5. FNCLCC grading system [73] 
Dedifferentiation 
Score 
Mitosis 
Score 
Necrosis 
Score 
Total 
Score 
Grade 
1: resembling normal 
2: definitive 
3: undifferentiated 
1: 0-9 / 10 HPF 
2: 10-19 / 10 HPF 
3: > 20 / 10 HPF 
0: None 
1: < 50% 
2: > 50% 
2 – 3 
4 – 5 
6 – 8  
1 
2 
3 
 
 2.4 Survival, disease progression and functional outcome 
Patients were seen at regular intervals as part of their cancer follow-up care following 
discharge. The follow-up care plan for these patients has been summarized in table 
6. Data regarding progression of disease (local recurrence or metastasis) as well as 
overall survival were also collected. In cases of disease progression, the site of 
metastasis as well as secondary amputations due to local recurrence were recorded. 
 
Table 6. Follow-up care plan following hospital discharge for our patients at 
Frankfurt Höchst Clinical Center 
Tumor  
grade 
Frequency of postoperative 
clinical examinations 
Frequency of postoperative 
radiological examinations 
High/ 
intermediate 
Years 1 and 2: Three monthly 
Year 3: Six monthly 
Years 4 and 5: Annually 
MRI of primary site with every 
clinical examination. 
Chest CT scans: Six monthly 
Low Years 1 and 2: Six monthly 
Years 3, 4 and 5: Annually 
MRI of primary site with every 
clinical examination. 
Chest CT scan / radiograph of 
chest: Annually 
 
The functional outcome of our patients was assessed by examining the lower limb for 
function and range of motion. The results of the clinical examination were then 
categorized as either normal, limited or severely limited. Limited function was defined 
as a reduced active knee flexion of between 90° and 110° and / or weakness of the 
intrinsic foot muscles; movement of the foot was possible but reduced. Patients with 
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severely limited function of the leg had a severely reduced knee flexion of less than 
90° and minimal or no movements of the foot were possible. Patients were also 
asked about the presence of chronic swelling, paresthesia or chronic pain as well as 
their walking range and the use of walking aids. Finally, the musculoskeletal tumor 
society [MSTS] rating score modified by Enneking was calculated in the 20 surviving 
patients at approximately one year postoperatively during the outpatient follow up 
examination [74]. This scoring system is summarized in table 7 and consists of six 
main categories: pain, limb function, walking aids, walking distance, gait and 
emotional acceptance. A score of 0 – 5 is assigned to each category; higher scores 
are associated with a greater level of function. The scores out of a total of 30 were 
then converted to percentages. Finally, as part of their most recent follow-up visit, 
patients were asked about their satisfaction with limb preservation and whether they 
would make the same choice again. The answers, either a “yes” or “no”, were then 
recorded in our database. 
 
Table 7. Musculoskeletal Tumor Society [MSTS] Rating Score modified by 
Enneking [74] 
Pain Function Walking 
aids 
Walking 
distance 
Emotional Score 
Severely 
disabling 
Complete 
restriction 
Two 
crutches or 
wheelchair 
Unable to walk 
independently 
Dislikes 0 
Moderately 
disabling 
Partial 
restriction 
One crutch/ 
walking 
stick 
Only mobile 
indoors 
Accepts 1 
Intermediate Intermediate Occasional 
use of 
crutch 
Severely 
limited 
outdoors 
Intermediate 2 
Modest Recreational 
restriction 
Brace Limited Satisfied 3 
Mild Mildly 
restricted 
Orthotics Mildly limited Content 4 
No pain No restriction None No limitation Enthused 5 
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2.5 Statistical methods: 
Statistical analyses were performed with IBM SPSS Statistics 24. Continuous 
variables were expressed as median and range and correlations between continuous 
variables were explored using the Pearson correlation test [75]. 
The X2 test and Fisher exact test were used when comparing categorical variables. 
When comparing continuous variables, the Kolmogorov-Smirnov-Lilliefors-Test was 
implemented in determining whether data followed a normal distribution. The 
independent t-Test was used with normally distributed data and the Wilcoxon-Mann-
Whitney-U-Test with non-normally distributed data [75].  
The Kaplan-Meier method was used to calculate the survival and disease 
progression curves and the log-rank test was used to calculate differences between 
groups. Within the exploratory nature of this work, we considered a p value of ≤0.05 
significant [75]. 
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3. RESULTS 
 
3.1 General and preoperative characteristics 
A total of 364 patients with STS underwent surgical resection between January 1st 
2010 and January 31st 2017. Truncal and retroperitoneal STS was recorded in 166 
patients (45.6%), and 19 patients (5.2%) were diagnosed with upper extremity STS. 
These patients were excluded from our analysis.  
A total of 179 patients (49.2%) were found to have lower limb STS, of which 27 
patients (15.1% of all patients with lower limb STS) had sciatic nerve involvement 
(type A or B) and were included for further analysis (n = 27). Figure 10 summarizes 
the results of the patient selection process. 
 
Figure 10. Patient selection 
 
 
 
 
 
 
 
 
 
 
 
3.2 Perioperative variables 
27 Patients with STS of lower 
extremity with sciatic nerve 
involvement (type A or B) 
Excluded: 166 patients with 
retroperitoneal/truncal STS 
Excluded: 19 patients with STS of upper 
limb 
Excluded: 152 patients with STS of 
lower limb without sciatic nerve 
involvement 
364 Patients with STS who 
underwent surgical resection 
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The median age of these 27 patients was 57 years (Interquartile Range [IQR] 46 – 74 
years). Six out of 27 patients (22.2%) presented with a local recurrence while the 
remaining 21 patients (77.8%) presented with primary tumors. None of the patients 
presented with metastatic disease. The tumor entity was confirmed in all cases via 
biopsy or prior excision. Based on our proposed classification system, radiological 
tumor encasement of the sciatic nerve greater than 180° (type A) was demonstrated 
in 8 patients (29.6 %) and direct contact with the sciatic nerve less than 180° (type B) 
was displayed in the remaining 19 patients (70.4 %). Concurrent vascular 
involvement was confirmed in 6 cases (22.2%). Additional general and preoperative 
characteristics are summarized in table 8. 
 
Table 8. General and preoperative characteristics 
 
Characteristic   Number of patients (n = 27)  % 
Gender 
 Male     12     44.4 
 Female    15     55.6 
Side 
 Right     16     59.3 
 Left     11     40.7 
Presentation status 
 Primary tumor   21     77.8 
 Local Recurrence    6     22.2 
Sciatic Nerve Involvement 
 Type A     8     29.6 
 Type B    19     70.4 
Neoadjuvant therapy 
 External radiation therapy  10     37.0 
 Chemotherapy    6     22.2 
 Isolated limb perfusion   5     18.5 
Adjuvant therapy 
 External radiation therapy   8     29.6 
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 Chemotherapy    6     22.2 
 
3.2 Perioperative variables 
All tumor resections were carried out by one experienced surgeon (MS). A 
macroscopically complete resection without amputation was achieved in all patients. 
The median duration of surgery was 5.17 hours (IQR: 3.92 – 6.54 hours). The 
preoperative radiological categorization of type A and type B nerve involvement was 
confirmed intraoperatively in all 27 cases. Eight patients (29.6%) with type A sciatic 
nerve involvement underwent complete resection of the sciatic nerve and the 
remaining 19 patients with type B nerve involvement underwent epineural nerve 
dissection. Liposarcoma was the most common histopathologic entity (48.1%), with 9 
out of 13 liposarcomas diagnosed as low-grade (G1), 3 intermediate-grade (G2) 
liposarcomas and one high-grade (G3) liposarcoma. The median maximum tumor 
diameter measured by the pathologist following resection was 15 cm (IQR: 8.5 – 26.5 
cm). The microscopically negative margin rate in our series was 92.6% with a median 
margin size of 5 mm (IQR: 3 – 10 mm). Two patients with positive margins (R1), both 
with type B neural involvement, were disease-free at the latest follow-up 
appointments (22 and 17 months postoperatively). One of these patients was also 
treated with neoadjuvant radiotherapy and the other patient received adjuvant 
radiation therapy. Adjuvant radiation therapy (60-66 Gy total dose) was administered 
to 7 patients (25.9%) and one patient (3.7%) received adjuvant radiochemotherapy. 
Five other patients (18.5%) were subject to adjuvant chemotherapy. Table 9 
summarizes additional operative and histopathologic findings.  
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Table 9. Operative and histopathologic findings 
Characteristic        Number of patients (n = 27)     % 
Thigh compartment involvement 
(involvement of multiple compartments possible) 
 Posterior     27    100 
 Medial     19    70.4 
 Anterior     14    51.9 
Bone stripping      21    77.8 
Plastic Reconstruction 
 Local skin flap    4    14.8 
 Local musculocutaneous flap  21    77.8 
 Pedicled flap     2    7.4 
Histologic Entity 
 Liposarcoma (all subtypes)    13    48.1 
Pleomorphic Sarcoma (all subtypes) 11    40.7 
 Malignant giant cell tumor   1    3.7 
 Myxofibrosarcoma    1    3.7 
 Primitive neuroectodermal tumor  1    3.7 
Grade 
 Low Grade (G1)    10    37.0 
 Intermediate Grade (G2)   5    18.5 
 High Grade (G3)    12    44.4 
Margin 
 CR with negative margins (R0)  25    92.6 
 CR with positive margin (R1)  2    7.4 
 
3.3 Postoperative morbidity 
A total of 20 patients (74.1%) developed a surgical morbidity and 6 patients (22.2%) 
experienced medical complications postoperatively. Wound related morbidity, such 
as skin necrosis, wound dehiscence or infection, was the most common complication 
affecting 10 patients (37.0%), followed by hematoma or seroma which affected 6 
patients (22.2%). Two patients (7.4%) also suffered a pathological fracture of the 
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operated extremity following discharge; two months postoperatively for one patient 
and almost two years postoperatively for the other patient. Both patients had also 
undergone adjuvant radiation therapy. Hospital mortality was zero and the median 
duration of postoperative hospital stay was 30 days (IQR: 22 – 48 days). Table 10 
provides a list of all postoperative complications. 
 
Table 10. Postoperative Morbidity 
Complication        Number of patients (n = 27)  % 
Surgical Complications 
 Wound necrosis / dehiscence  10    37.0 
 Hematoma / seroma   6    22.2 
 Fracture     2    7.4 
 Bleeding     1    3.7 
Reoperations     13    48.1 
Medical Complications 
 Pneumonia     2    7.4 
 Urinary tract infection   2    7.4 
 Sepsis     1    3.7 
 Deep venous thrombosis   1    3.7 
Hospital Mortality     0    0 
 
3.4 Oncological outcome 
Patients were followed up for a maximum of 5 years postoperatively. The median 
postoperative follow-up duration of our patients was 23 months (IQR 15.5 – 50 
months). Eight patients (29.6%) were found to have recurrence of disease (local 
recurrence or metastasis). All of these 8 patients had metastatic disease, 3 of which 
(11.1%) also developed a local recurrence. The most common site of metastasis was 
the lung, with 5 patients developing pulmonary metastases. The type of disease 
progression, postoperative disease-free duration and survival in these 8 patients has 
been summarized in table 11. A secondary limb amputation was carried out in one 
patient with a high grade (G3) pleomorphic sarcoma due to a local recurrence.  
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Table 11. Progression of disease  
Site of metastases Local 
recurrence 
Postoperative disease-
free duration (months) 
Postoperative 
survival (months) 
Pulmonary 
Hepatic and bone 
Pulmonary and hepatic 
Pulmonary 
Pulmonary 
Pulmonary 
Bone 
Retroperitoneal 
No 
Yes 
No 
Yes 
No 
Yes 
No 
No 
2 
4 
12 
13 
9 
6 
10 
7 
3 
29 
54* 
15 
14 
38* 
25 
19 
*
patients are still alive 
The overall mortality rate in our series was 25.9% (n = 7), with a tumor related 
mortality rate of 22.2% (n = 6). The median survival was not reached in our cohort. 
For the 8 patients who developed progression of disease, the median survival was 21 
months. A significant association between the development of metastasis and 
mortality was demonstrated by the Kaplan-Meier survival analysis (p < 0.001), as 
shown in Graph 1. 
Graph 1. Development of metastatic disease and overall survival  
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Various general, perioperative and histopathologic parameters were investigated for 
their association with disease progression or mortality. Patient age, initial 
presentation with recurrent disease, tumor size, tumor histology, type of nerve 
resection, duration of surgery and duration of hospital stay were not found to have a 
statistically significant impact on the development of postoperative complications, 
disease progression or overall survival. 
The resection margin positively correlated with postoperative survival (p = 0.014). A 
simple scatterplot of the relationship between the size of the resection margins and 
postoperative survival is depicted in Graph 2. There was also a significant correlation 
between the size of the tumor and the duration of surgery (p = 0.007). The 
relationship between these two variables has also been displayed in a simple 
scatterplot (Graph 3). There was, however, no significant association between the 
duration of surgery and the development of postoperative surgical complications (p = 
0.858). 
 
Graph 2. Scatterplot representing relationship between resection margin size 
and postoperative survival (p = 0.014) 
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Graph 3. Scatterplot representing relationship between size of tumor and 
duration of surgery (p = 0.007) 
 
 
Intermediate and high-grade tumors (G2 and G3) were significantly associated with 
the development of distant metastatic disease (p = 0.010) as well as mortality (p = 
0.020), compared to low grade tumors (G1). The Kaplan-Meier survival curve for 
different tumor grades (p = 0.023) is displayed in Graph 4. 
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Graph 4. Tumor grade (G1/G2/G3) and overall survival (p = 0.023) 
   
 
Tumor infiltration of the sciatic nerve was histopathologically confirmed in only one 
patient (3.7%) with a G3 primitive neuroectodermal tumor (PNET), as displayed in 
figures 11, 12, 13 and 14. The preoperative radiographic imaging of this tumor 
demonstrated nerve encasement. Figures 15 and 16 demonstrate histopathological 
nerve encasement without nerve infiltration in a patient with a G3 UPS. An example 
of histopathological nerve contact without encasement is shown in figure 17. 
 
Figure 11. Hematoxylin and eosin (H&E) stain of nerve infiltration in a patient 
with a G3 PNET (under ϫ 100 magnification) 
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Figure 12. H&E stain of nerve infiltration in a patient with a G3 PNET (under ϫ 
400 magnification) 
Nerve infiltrated by 
residual tumor tissue 
Residual tumor 
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Figure 13. Elastica van Gieson (EvG) stain of nerve infiltration in a patient with 
a G3 PNET (under ϫ 400 magnification) 
 
Residual tumor 
Nerve 
Residual tumor 
Nerve 
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Figure 14. Immunohistochemical Cytokeratin (CK) CAM 5.2 stain (under ϫ 400 
magnification) of residual tumor cells after neoadjuvant chemotherapy in a 
patient with a G3 PNET  
 
Figure 15. H&E stain of nerve encasement without infiltration in a patient with a 
G3 UPS (under ϫ 100 magnification) 
 
Residual 
tumor cells 
Sciatic nerve 
The black line demonstrates 
the border of residual tumor 
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Figure 16. H&E stain of nerve encasement without infiltration in a patient with a 
G3 UPS (under ϫ 400 magnification) 
 
Figure 17. H&E stain of nerve contact without encasement or infiltration in a 
patient with a G3 UPS (under ϫ 100 magnification) 
 
Tumor cells 
encasing nerve 
Sciatic nerve 
Nerve 
The black line demarcates the 
boarder of residual tumor 
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3.5 Functional outcome 
In addition to carrying out the necessary follow-up screening diagnostics, patients 
were also clinically examined and were asked questions regarding their functional 
status and limitations in carrying out their activities of daily living. The main functional 
outcomes which were measured are summarized in Table 12. 
Complete sciatic nerve resection was found to be significantly associated with the 
development of leg edema (p = 0.017), chronic pain (p = 0.003), reduced leg function 
(p < 0.001) and lower MSTS scores (p = 0.001) when compared to epineural nerve 
dissection.  
Table 12. Functional outcome 
Functional component   Number of patients (n = 27)  % 
Chronic leg edema     15    55.6 
Paresthesia      18    66.7 
Chronic pain      12    44.4 
Walking aids/braces    17    63.0 
Leg function/range of motion    
 Severely limited/no function  9    33.3 
 Limited     12    44.4  
 Normal     6    22.2 
Walking distance 
 Normal     15    55.6 
 100-500m     9    33.3 
 <100m     3    11.1 
  
The MSTS scores of the 20 surviving patients was calculated at their latest follow-up 
appointments, with a median follow-up duration of 35 months postoperatively.  50% 
of surviving patients had an MSTS score of 83% or greater. Five patients (25%) 
scored between 67% and 80% and the remaining 5 patients received a score of less 
than 67%. The MSTS scores have been summarized in table 13. 
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Table 13. MSTS scores 
MSTS score Number of patients (n = 27)   % 
25-30 (≥ 83%)                         10     50 
20-24 (67 - 80%) 5     25 
< 24 (< 67%)                                             5                                                 25 
 
The use of walking aids and/or orthoses is summarized in table 14. All 8 patients 
(100%) with type A sciatic nerve involvement wore a peroneal splint compared to two 
patients (11%) from the type B nerve involvement group. Three out of 8 patients 
(38%) with type A nerve involvement were only adequately mobile in a wheelchair 
compared to 2 patients (11%) with type B involvement. Apart from one patients, all 
other patients who required a wheelchair for their mobilization were over 70 years 
old. A total of 15 patients (56%) did not require any walking aids at their latest follow 
up appointment, 3 of which were patients with type A nerve involvement. 
Patients were asked how they felt about undergoing limb sparing surgery and 
whether they had any regrets during their follow up appointments. All patients, 
including those with complications or recurrence of disease, were satisfied with their 
decision in opting for limb sparing surgery as opposed to amputation of the affected 
extremity. 
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Table 14. Use of walking aids and orthoses  
Type of Neural 
Involvement 
Walking Aids Orthoses  
A None Peroneal splint 
A None Peroneal splint 
A Wheelchair Peroneal splint 
A Walking stick Peroneal splint 
A Wheelchair Peroneal splint 
A Wheelchair Peroneal splint 
A None Peroneal splint 
A Walking stick Peroneal splint 
B None None 
B None None 
B None Peroneal splint 
B None None 
B Wheelchair None 
B None None 
B None None 
B Walking stick None 
B Walking stick None 
B None None 
B Zimmerframe None 
B None None 
B None None 
B None None 
B None None 
B Walking stick None 
B Zimmerframe None 
B None Peroneal splint 
B Wheelchair None 
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4. DISCUSSION 
 
4.1 Proposed classification system 
Our proposed classification system provides a simple and clinically applicable 
algorithm to facilitate the choice between nerve resection or epineural dissection in 
patients undergoing limb sparing surgery due to STS with sciatic nerve involvement. 
The significance of this classification lies in its potential to encourage a limited 
epineural dissection in eligible patients (type B neural involvement) without 
compromising the oncological outcome or unnecessarily sacrificing the leg function. 
In addition, this classification may help establish limb sparing surgery as the 
procedure of choice in patients with type A sciatic nerve involvement. The initial 
assessment of nerve involvement is radiological followed by an intraoperative 
confirmation. Hence, this classification may be used in the preoperative setting to 
inform and consent the patient on the expected procedure and its’ alternatives.  
In addition, the already established classification system for vascular involvement in 
STS by Schwarzbach et al. [31, 32] could also be combined with our proposed 
classification system for nerve involvement, enabling STS with neurovascular 
involvement to be more accurately classified. Tumors with arterial involvement, no 
vein involvement and nerve encasement > 180° would, for example, be classified as 
a type IIA STS. This could be used to generate an individualized plan for the surgical 
procedure and thus improve the resection strategy within a multimodal treatment 
concept. A precise surgical concept based on the proposed classification system of 
neural and vascular involvement could allow the planning of additional radiotherapy. 
For example, the preoperative identification of regions with minimal safety margins 
and thus neoadjuvant external beam radiotherapy could lead to function-sparing 
surgery without compromising the oncological outcome.   
 
4.2 Discussion of oncological results and review of current literature 
Our study assessed the functional and oncological outcomes in a carefully selected 
cohort of 27 patients with STS and sciatic nerve involvement treated in a specialist 
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center. To our knowledge, it is the second largest series of patients (following the 
cohort of 94 patients examined by Clarkson et al.) with this diagnosis published to 
date. Reasonable oncological outcomes were demonstrated in our patient series 
following limb sparing surgery. The frequency of local recurrence (11.1%) and distant 
metastasis (29.6%) compare well with a large prospective study of 1,041 patients 
with STS of the extremities, which reported rates of 17% and 22% respectively [24]. 
More recent studies, however, demonstrated local recurrence rates of 10% or less 
[19, 34, 57, 58, 76]. Our local control rate of 88.9% is also comparable to most 
modern series, which report local control rates of approximately 90% [19]. Pisters et 
al. found that high-grade lesions were a significant prognostic factor in the 
development of metastatic disease, which was also confirmed in our patient cohort 
[24].   
Liposarcoma and pleomorphic sarcoma were the two most common histopathologic 
entities in our study population, which is analogous to the current literature [19]. 
However, the histopathologic subtype was not found to be of prognostic significance 
in our study, despite being shown to be an independent prognostic factor in other 
studies [23, 24]. This may be due to the small number of patients and the resulting 
low statistical power in our series. 
Resection margins have also been shown to be an independent prognostic factor in 
local and distant disease control [23, 77, 78]. Stojadinovic et al. found that positive 
margins double the risk of local recurrence in a large cohort of 2084 patients [79]. 
The importance of the surgical resection margins was confirmed in our study, as the 
size of the negative margins significantly correlated with survival after surgery. 
However, negative margins are not always achievable, particularly when the tumors 
are located near vital neurovascular structures. O’Donnell et al. found that sparing 
adjacent critical structures did not increase the risk of a local recurrence or reduce 
survival rates and led to superior functional outcomes in 169 patients with STS and 
positive margins following surgical tumor resection [80]. This study, however, 
involved a heterogeneous group of patients with STS in diverse anatomic locations 
with varying neurovascular involvement. The results should therefore be interpreted 
with caution, particularly when discussing positive margins in our specific cohort of 
patients with sciatic nerve involvement. 
- 45 - 
 
Aggressive local treatment such as higher radiation doses followed by a wide 
excision or even amputation is usually recommended when the surgical resection 
margins are positive, particularly when the positive margins are unplanned or 
macroscopically visible [9].  Patient outcomes have however been shown to be 
inferior despite aggressive treatment, highlighting the importance of accurate 
diagnosis and management of these lesions in the initial treatment phase [9].  
Presentation with local recurrent disease and positive margins following tumor 
resection have been shown to be prognostic factors for the development of a local 
recurrence in several studies [24, 81]. Presentation with locally recurrent disease has 
even been shown to be a significant independent risk factor for the development of a 
further local recurrence following resection of recurrent disease [82]. This was not 
observed in our study, probably due to the small number of postoperative local 
recurrences, occurring in only 3 of our patients. 
The 5-year overall survival of patients with metastatic STS has been shown to be 
poor [19]. Our study confirmed the correlation between the development of metastatic 
disease and mortality, which has been shown in previous studies [24]. This highlights 
the importance of improving systemic control of disease. Williard et al. reported a 
tumor related mortality rate of greater than 50% despite local tumor control, 
independent of whether patients were treated with limb amputation or limb sparing 
surgery, further emphasizing the need to improve systemic disease control [83]. 
Pisters et al. analyzed numerous prognostic factors for STS of the extremities in their 
large patient cohort and found that the adverse prognostic factors for developing a 
local recurrence differ from those predicting metastatic disease and tumor related 
mortality [24]. The authors therefore proposed two separate staging systems for 
patients with STS, identifying patients at risk of developing a local recurrence and 
another system for those at risk of distant metastatic disease and tumor related 
mortality. These distinctive staging systems would allow an early classification of 
patients at high risk of local or distant disease recurrence and thus the prompt 
initiation of local or systemic adjuvant therapy, respectively [24]. These two distinct 
staging systems and their potential therapeutic consequences could be further 
validated in future research.   
Our series consists of primarily large, deep and in 7 cases recurrent STS with sciatic 
nerve involvement undergoing compartmental tumor resections in a multimodal 
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therapeutic approach. The most common postoperative complications in our study 
were wound complications, arising in 37% of our patients, followed by hematomas 
and seromas, occurring in 22.2% of cases. These factors contributed to a high 
reoperation rate of 48.1% as well as a median hospital stay of 30 days. A wound 
complication rate of 34.4% has been reported in en bloc resections without 
intraoperative adjuvant treatment modalities [53]. A long duration of surgery, patients 
over 40 years of age and adjuvant intraoperative treatment modalities such as 
radiotherapy, brachytherapy or regional chemotherapy have been identified as risk 
factors for developing wound complications [53, 84]. Duration of surgery, patient age 
and adjuvant treatments were not found to be associated with the development of 
wound complications in our study. These results should however be interpreted with 
caution due to the limited number of patients in our series.  
 
4.3 Discussion of functional results and review of current literature 
Some authors have previously recommended hip disarticulation or hindquarter 
amputation when complete resection of the sciatic nerve is necessary as a limb 
without tactile sensations was not considered worth saving from a functional 
perspective [37, 38, 40, 81, 85]. Several authors have, however, reported acceptable 
functional outcomes after complete resection of the sciatic nerve [44, 50-52, 86] with 
some studies demonstrating superior function when comparing sciatic nerve 
resection with amputation of the leg [87, 88]. The function of the leg is also 
dependent on the level of the sciatic nerve resection as distal resections have been 
shown to lead to a superior function of the salvaged leg [49].  
In our study, all patients were satisfied with their decision to undergo limb-sparing 
surgery, despite functional limitations which were particularly apparent in the sciatic 
nerve resection group. Patients should be informed about requiring walking aids and 
orthoses for the rest of their life after resection of the sciatic nerve due to the partial 
muscle paralysis, especially in muscles controlling the foot. It is also important that 
patients are properly instructed preoperatively regarding adequate foot care of their 
postoperative insensate feet to minimize skin complications, particularly the 
development of foot ulcers, which can ultimately lead to a secondary amputation of 
the limb [51]. The foot care and treatment are analogous to patients with diabetic foot 
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syndrome or polyneuropathy of other causes and can be carried out in an outpatient 
center for diabetic foot syndrome.  
All of our patients with type A sciatic nerve involvement wore a peroneal splint 
compared to just 11% of patients from the type B nerve involvement group. With 
regards to mobility aids, 38% of patients with type A nerve involvement were only 
adequately mobile in a wheelchair compared to just 11% with type B involvement. 
The use of a wheelchair also appears to be strongly associated with age, as four out 
of five patients requiring a wheelchair were over the age of 70. These results have 
important implications when consenting patients preoperatively. For example, 
patients with type A nerve involvement will be informed that they require a peroneal 
splint postoperatively and that they will most likely require walking aids particularly if 
they are over the age of 70. Preoperative physiotherapy and simulation of peroneal 
nerve injury could also be considered as a form of prophylaxis from falls.  
The extent of nerve resection was not found to affect the local or distant recurrence 
rate or have an impact on survival in our study. Similar local recurrence rates were 
also reported by Clarkson et al. in their cohort of 94 patients when comparing sciatic 
nerve resection with epineural nerve dissection [52]. Their study also demonstrated 
superior functional outcomes with patients receiving epineural nerve dissection 
compared to complete nerve resection. Our study further confirms these findings, as 
there was a significant association in the development of chronic leg edema, chronic 
pain, poor leg function as well as lower MSTS scores in the group of patients who 
underwent complete sciatic nerve resection when compared to the patients treated 
with an epineural nerve dissection.  
None of the patients in our study underwent reconstruction of the sciatic nerve after 
its resection. Whether such reconstruction is truly indicated remains controversial. 
Some authors do not believe that it is justified as preservation of leg function cannot 
be guaranteed and the reconstruction prolongs the duration of surgery, increasing 
the risk of postoperative complications such as delayed wound healing and infections 
[48, 51]. The gold standard for nerve reconstruction is grafting of autogenic nerve 
[48]. Melendez et al. demonstrated positive functional outcomes in 5 patients with 
STS of the thigh with sciatic nerve involvement who underwent autogenic common 
peroneal nerve reconstruction. The sural nerve was also used in 2 of these patients. 
All 5 patients recovered metatarsal sensation and could walk with the aid of an ankle 
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joint brace [89]. Further research regarding the regeneration potential of 
reconstructed sciatic nerves under the influence of chemotherapy and radiation 
therapy is warranted [51]. 
 
4.4 Limitations 
The present study is one of the largest published series of patients with STS and 
sciatic nerve involvement to date, as most prior studies were limited to a cohort of 
less than 20 patients [23, 49-51]. Nevertheless, the small absolute number of patients 
limit the statistical power of our analysis. In addition, the median follow-up duration in 
our study was 23 months and patients were followed up to a maximum duration of 5 
years postoperatively. As the follow up duration in some patients was short, a repeat 
analysis of this cohort could be carried out in 5 and in 10 years to further assess the 
long term functional and oncological outcomes, with particular focus on patient 
survival. 
It is essential to validate our proposed classification and to assess the potential role 
of prognostic parameters, such as tumor grade, in further optimizing patient and 
procedure selection. The tumor grade may influence the extent of surgical resection 
and could potentially be incorporated into the treatment algorithm. For example, a 
nerve-sparing surgical resection may be considered in a young patient with a low 
grade liposarcoma and type A sciatic nerve involvement to minimize the loss of 
function. This is because these tumors rarely metastasize and the risk of local 
recurrence may be reduced by incorporating adjuvant or neoadjuvant radiotherapy. It 
is also necessary to assess the applicability of this classification for different nerves 
separately due to the variations in their sensorimotoric functions and in the degree of 
compensation following nerve resection. 
It is also important to note only 1 patient (3.7%) in our study with a G3 primitive 
neuroectodermal tumor and sciatic nerve encasement greater than 180° revealed 
histopathologic nerve infiltration. This low rate of histopathologic infiltration may 
encourage a more nerve-preserving approach whenever technically possible.  
The functional evaluation of our patients was largely centered on the musculoskeletal 
tumor society rating score modified by Enneking [74]. There are several established 
scores and systems available for assessing the function of patients after undergoing 
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limb sparing operations. Davis et al. compared the Toronto extremity salvage score 
with the musculoskeletal tumor society scores [74, 90] and the short form 36 [91] for 
the postoperative functional assessment of 97 patients with STS of the lower 
extremity [92]. The Toronto extremity salvage score was found to be superior 
regarding the measurement properties and was recommended as an efficient and 
reliable functional evaluation method in patients receiving limb sparing surgery [92]. 
Further analyses of our cohort could therefore incorporate the Toronto extremity 
salvage score as part of the functional outcome assessment. 
The effects of neoadjuvant and adjuvant therapy on both functional and oncological 
outcomes were also not addressed in our current study and could be studied in future 
analyses. Furthermore, the role of PET scans particularly for the early detection of 
metastatic disease could be investigated and compared to patients who did not 
receive PET scans as part of the postoperative surveillance. PET scans have also 
been shown to play a valuable role in the preoperative prognostic assessment of 
patients with resectable STS [11]. Postoperative functional data could also be 
compared to preoperative functional data, as it has been suggested that patients with 
worse function preoperatively have a higher capacity to improve postoperatively [50]. 
There was no significant association found between the involved thigh compartments 
and postoperative morbidity, functional or oncological outcomes in our study. This 
may also be due to the small size of our study population. Rimner et al. investigated 
the influence of compartmental involvement on the patterns of morbidity and outcome 
in a cohort of 255 patients with STS of the thigh [93]. The authors found no significant 
difference between the three thigh compartments regarding local and distant tumor 
control. The rates of wound complications requiring reoperations and postoperative 
edema were however significantly higher in patients with medial-compartment tumors 
[93]. In addition, nerve damage was more frequent in posterior-compartment tumors 
[93]. These differences in the involved thigh compartments could be further 
investigated in future research as the management of patients with STS of the thigh 
could potentially vary and be adjusted depending on the involved compartments. 
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4.5 Conclusion 
This study describes the multimodal treatment options, functional and oncological 
results in a carefully selected patient cohort with STS and sciatic nerve involvement. 
It is the first study to date to propose a classification for the extent of sciatic nerve 
involvement in STS and to suggest a surgical treatment algorithm. The surgical 
strategies of choice in patients with sciatic nerve involvement in our study were en 
bloc tumor resection with either epineural nerve dissection or sciatic nerve dissection 
in a limb-sparing treatment approach. Both techniques were associated with 
adequate local tumor control and excellent limb salvage rates.  
Patients were satisfied with limb-sparing surgery even when the sciatic nerve was 
resected and despite the considerable amount of associated short and long-term 
physical impairment. The perioperative data of our patient cohort including the high 
rate of perioperative wound morbidity, reoperation rate and increased length of 
hospital stay associated with limb salvage surgery allows improved understanding of 
the perioperative course in this subset of sarcoma patients. This knowledge helps 
inform patients preoperatively about the expected postoperative course including 
likely physical impairment and need for orthotics and walking aids. 
Precise classification of nerve involvement may be useful in selecting the appropriate 
degree of nerve resection, without compromising the oncological outcome or 
unnecessarily sacrificing leg function. Additional studies are necessary to validate 
and optimize this classification. 
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5. SUMMARY 
The surgical resection of lower limb soft tissue sarcomas with sciatic nerve 
involvement presents a significant surgical and oncological challenge. In the past, 
sciatic nerve involvement was an indication for limb amputation. However, recent 
studies have shown acceptable functional outcomes and no significant difference in 
overall survival rates for limb sparing surgery. Current treatment strategies are 
therefore more targeted towards limb preservation. 
The aim of our study was to evaluate the outcomes of limb sparing surgery of soft 
tissue sarcomas with sciatic nerve involvement in a cohort of adult patients treated in 
a specialist center. We also proposed a classification for sciatic nerve involvement 
and a treatment algorithm for soft tissue sarcomas of the lower extremity. 
Demographic, clinical and oncological data of 27 patients with soft tissue sarcomas 
of the lower extremity with sciatic nerve involvement undergoing limb sparing 
surgery at the Clinical Center Frankfurt Höchst between January 2010 and January 
2017 were collected on an ongoing basis in a computerized database and 
retrospectively analyzed. Nerve involvement of lower limb soft tissue sarcomas was 
classified as follows: Type A for nerve encasement greater than 180° and type B for 
nerve contact. Patients with type A tumors underwent sciatic nerve resections 
whereas patients with type B tumors were treated with an epineural nerve dissection. 
Disease progression was observed in 8 patients (29.6%) with a local recurrence rate 
of 11.1% and distant metastasis in 29.6% of patients. The overall survival rate was 
74%. Tumor grade was the single parameter significantly associated with metastatic 
disease and overall survival. The type of nerve resection significantly influenced the 
functional outcome but had no significant impact on oncological outcome or overall 
survival. 
To our knowledge, this is the first study to date to classify the extent of nerve 
involvement in soft tissue sarcomas and to suggest a treatment algorithm based on 
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the classification. We have demonstrated that acceptable oncological and survival 
outcomes can be achieved for patients undergoing limb sparing surgery with no 
significant difference between patients undergoing complete nerve resection or 
epineural dissection of the sciatic nerve. Hence, precise classification of nerve 
involvement is essential in selecting the appropriate degree of nerve resection, 
without compromising oncological outcome or unnecessarily sacrificing the 
functional outcome.  
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